Charles Schwab Investment Management Inc. Sells 7,571 Shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA)

Charles Schwab Investment Management Inc. trimmed its position in shares of Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) by 4.7% during the fourth quarter, Holdings Channel.com reports. The firm owned 154,827 shares of the biotechnology company’s stock after selling 7,571 shares during the period. Charles Schwab Investment Management Inc.’s holdings in Enanta Pharmaceuticals were worth $890,000 as of its most recent SEC filing.

A number of other large investors also recently modified their holdings of ENTA. China Universal Asset Management Co. Ltd. bought a new position in shares of Enanta Pharmaceuticals in the fourth quarter valued at $26,000. Connor Clark & Lunn Investment Management Ltd. acquired a new stake in shares of Enanta Pharmaceuticals in the 3rd quarter worth about $122,000. Barclays PLC raised its holdings in shares of Enanta Pharmaceuticals by 294.2% in the 3rd quarter. Barclays PLC now owns 27,438 shares of the biotechnology company’s stock worth $285,000 after acquiring an additional 20,478 shares during the last quarter. Wellington Management Group LLP bought a new position in Enanta Pharmaceuticals in the 3rd quarter valued at about $360,000. Finally, Walleye Capital LLC boosted its stake in Enanta Pharmaceuticals by 96.4% during the 3rd quarter. Walleye Capital LLC now owns 43,899 shares of the biotechnology company’s stock valued at $455,000 after purchasing an additional 21,550 shares during the last quarter. 94.99% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on the company. StockNews.com raised Enanta Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Wednesday, February 19th. HC Wainwright reissued a “buy” rating and issued a $18.00 price target on shares of Enanta Pharmaceuticals in a research report on Tuesday, February 11th. Finally, JMP Securities restated a “market outperform” rating and set a $21.00 price objective on shares of Enanta Pharmaceuticals in a research note on Tuesday, February 11th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Enanta Pharmaceuticals currently has an average rating of “Moderate Buy” and an average price target of $17.25.

Insider Activity at Enanta Pharmaceuticals

In related news, CEO Jay R. Luly acquired 45,000 shares of the company’s stock in a transaction that occurred on Wednesday, February 12th. The shares were acquired at an average price of $5.69 per share, with a total value of $256,050.00. Following the acquisition, the chief executive officer now owns 846,638 shares of the company’s stock, valued at approximately $4,817,370.22. This trade represents a 5.61 % increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. 13.89% of the stock is currently owned by company insiders.

Enanta Pharmaceuticals Stock Down 2.6 %

Shares of NASDAQ ENTA opened at $5.71 on Monday. The company has a market capitalization of $121.81 million, a PE ratio of -1.15 and a beta of 0.48. The stock’s 50 day moving average price is $6.41 and its 200-day moving average price is $8.19. Enanta Pharmaceuticals, Inc. has a twelve month low of $4.71 and a twelve month high of $17.80.

Enanta Pharmaceuticals (NASDAQ:ENTA) last announced its quarterly earnings data on Monday, February 10th. The biotechnology company reported ($1.05) EPS for the quarter, topping the consensus estimate of ($1.16) by $0.11. Enanta Pharmaceuticals had a negative net margin of 157.57% and a negative return on equity of 75.53%. As a group, research analysts expect that Enanta Pharmaceuticals, Inc. will post -4.65 EPS for the current fiscal year.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals, Inc, a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV.